New immunotherapeutic interventions have revolutionized cancer treatment. The immune responsiveness of acute myeloid leukaemia (AML) was first demonstrated by allogeneic stem cell transplantation. In addition, milder immunotherapeutic approaches are exploited. However, the long-term efficacy of these therapies is hampered by various immune resistance and editing mechanisms. In this regard, co-inhibitory signalling pathways have been shown to play a crucial role. Via up-regulation of inhibitory checkpoints, tumourreactive T cell and Natural Killer cell responses can be strongly impeded. Accordingly, the introduction of checkpoint inhibitors targeting CTLA-4 (CTLA4) and PD-1 (PDCD1, CD279)/PD-L1 (CD274, PDCD1LG1) accomplished a breakthrough in cancer treatment, with impressive clinical responses. Numerous new co-inhibitory players and novel combination therapies are currently investigated for their potential to boost anti-tumour immunity and improve survival of cancer patients. Although the challenge here remains to avoid severe systemic toxicity. This review addresses the involvement of co-inhibitory signalling in AML immune evasion and discusses the opportunities for checkpoint blockers in AML treatment.
Acute myeloid leukaemia (AML) is characterized by uncontrolled clonal expansion and accumulation of immature cells of the myeloid lineage together with a block in cellular differentiation. This results in an excess of malignant cells (>20% blasts) in the bone marrow and peripheral blood, often accompanied by a lack of functional mature cells in the peripheral blood (O'Donnell et al, 2012) . The incidence of AML increases with age and the median age at diagnosis is 67 years (Sekeres, 2008) . Currently, long-term clinical remissions can be induced in 35-40% of adult AML patients who are 60 years or younger, as compared to 5-15% of AML patients above 60 years (Burnett, 2012) . Besides patient age, this survival rate also depends on the presence of cytogenetic or molecular genetic aberrations and patient health status. The outcome in older patients, who are unfit to receive intensive chemotherapy, is dismal, with a median survival of only 5-10 months .
Anti-leukaemic treatments build on intensive or reduced intensity/non-myeloablative remission-induction chemotherapy regimens to reduce tumour load and induce complete remission, followed by allogeneic stem cell transplantation (allo-SCT) in (very) poor risk patients. Allo-SCT was the first successful immunotherapy with curative potential in patients with haematological malignancies (cure rate 50-60%). Its clinical efficacy can be attributed to the graftversus-leukaemia (GVL) effect mediated by donor-derived allogeneic T cells and Natural Killer (NK) cells. Although older and medically less fit AML patients can benefit from reduced intensity or non-myeloablative conditioning protocols, relapse rates are high. Recently, the hypomethylating agents (HMA), azacitidine and decitabine, have been registered for elderly AML patients unfit to receive intensive chemotherapy, as HMA possess strong anti-leukaemic efficacy and are well-tolerated . To improve outcome post allo-SCT, the addition of HMA to the conditioning regimen as well as HMA administration as maintenance therapy post-transplant has been exploited (Cruijsen et al, 2016) . In addition, adjuvant cellular immunotherapies, including donor lymphocyte infusion (DLI), adoptive T cell transfer and dendritic cell (DC)-based vaccination, are being explored to boost GVL immunity.
Unfortunately, the beneficial GVL effect of allo-SCT is counterbalanced by high morbidity and mortality due to the induction of (severe) graft-versus-host-disease (GVHD). Furthermore, relapse remains the leading cause of treatment failure (de Lima et al, 2014) . This could be (partially) related to insufficient priming and/or induction of tumour-reactive T cells and NK cells. However, another cause could be immune evasion of the leukaemia cells via immunosuppressive mechanisms (Norde et al, 2011; Hobo et al, 2012; Ahci et al, 2017) . To improve disease-free and overall survival of AML patients, potent new adjuvant therapies are needed. Recent developments include novel chemotherapeutic agents and regimens (Cortes et al, 2015) , such as HMA, antibody-drug conjugates targeting e.g. CD33 and CD123, and dual affinity retargeting molecules like CD33 9 CD3 bispecific T cell engager (BiTE; AMG 330), CD123/CD3 duobody (JNJ-63709178) and CLEC12AxCD3 bispecific antibody MCLA-117 (Hoseini & Cheung, 2017) . Moreover, chimeric antigen receptor (CAR) T cell therapy is being developed for AML, however this might be problematic due to the non-restricted expression of AML-associated antigens (Lichtenegger et al, 2017) . In addition, molecular targeted therapies, including tyrosine kinase inhibitors directed against vascular endothelial growth factor receptor (VEGFR, also termed KDR), platelet-derived growth factor receptor (PDGFR, also termed PDGFRB) and Raf family kinases, are being explored. New kids on the block for AML treatment are the immune checkpoint inhibitors, which have shown impressive clinical efficacy in various solid cancers, including melanoma and lung cancer (Postow et al, 2015a) . Tumour responsiveness to checkpoint blockers is dependent on different parameters, including mutational load of the tumour, pre-existing antitumour immunity and checkpoint ligand (over) expression by the tumour (Menter et al, 2016) . Immunogenic tumours generally have numerous T cells in their local environment. Furthermore, tumours with high mutational load express (high levels of) neo-antigens, which can trigger powerful immune responses. Although the mutational load in AML is low, AML is an immunoresponsive malignancy as demonstrated by the response to allo-SCT and DLIs (Chang & Huang, 2013; Schumacher & Schreiber, 2015) . This review addresses the role of co-inhibitory molecules in immune evasion by AML and discusses the opportunities for checkpoint interference.
Immune checkpoint molecules in AML
Effective T cell activation requires multiple signals. First, the T-cell receptor (TCR) needs to interact with its cognate peptide presented in human leucocyte antigen (HLA) complex molecules on the antigen presenting cell (APC). Second, costimulatory signals provided by the CD28:B7 and tumour necrosis factor receptor families are essential. Furthermore, signalling via cytokine receptors contributes to adequate T cell activation. Tumour-reactive T cell responses can be directed against leukaemia-associated antigens (LAA), neoantigens expressed by residual leukaemia cells, or, in the context of allo-SCT, minor histocompatibility antigens (MiHA), which are peptide products derived from polymorphic genes that differ between recipient and donor (Bleakley & Riddell, 2004) . In contrast, NK cell activation is antigen-independent and solely relies on signals delivered by activating (including NKG2D [KLRK1] and DNAM-1 [CD226]) and inhibitory receptors (including HLA-I molecules). Upon activation, T cells and NK cells acquire effector functions, expand and attack non-self or altered cells.
Both activated T cells and NK cells express a wide range of co-inhibitory receptors. These immune checkpoints are critical for maintaining self-tolerance and resolving the immune response upon clearance of target cells (Fig 1) . However, these pathways are often employed by tumours to escape immune-mediated destruction (Postow et al, 2015a) . In haematological and solid malignancies, low expression of co-stimulatory ligands and high expression of co-inhibitory ligands has been associated with poor prognosis (Dong et al, 2002; Norde et al, 2011) . Furthermore, tumour-reactive T cells and NK cells have been shown to express multiple coinhibitory receptors on their surface. The sum of co-stimulatory and co-inhibitory signals determines the activation state, magnitude and duration of the T cell and NK cell responses, thereby tightly balancing tumour tolerance and elimination. The key players with a role in dampening anti-leukaemia immunity are discussed below.
CTLA-4
Cytotoxic T lymphocyte antigen 4 (CTLA-4; CTLA4; CD152) is a key co-inhibitory molecule expressed by activated CD4 + and CD8 + T cells, which competes with CD28 for binding to CD80 (B7-1) and CD86 (B7-2). Whereas CD28 is constitutively expressed on the membrane of na€ ıve T cells, CTLA-4 is mainly localized in the cytoplasm. Upon activation, CTLA-4 is rapidly mobilized to the T cell membrane where it outcompetes CD28, due to a 10-to 100-fold higher ligand binding affinity, and thereby dampens T cell responses. In addition, reports have shown that the YVKM motif in the cytoplasmic tail of CTLA-4 can directly inhibit T cell activation via SHP2 and serine/threonine phosphatase 2A (PP2A). Notably, CTLA-4 is also expressed by regulatory T cells (T regs ). The importance of CTLA-4 in regulating T cell homeostasis and central tolerance became evident in CTLA-4 knockout mice, which developed lethal lymphoproliferative disease with multi-organ T cell infiltration. Although CTLA-4 blockade was not very successful in in vitro models, mouse studies demonstrated its power to reverse T cell dysfunction in chronic viral infections and established tumour models (Fong & Small, 2008) . These data provided the rationale for the clinical exploration of anti-CTLA-4 treatment in cancer patients. The impressive results obtained in the phase III trial in metastatic melanoma patients, where patients achieved tumour regression and improved survival upon anti-CTLA-4 treatment, subsequently led to the approval of ipilimumab by the US food and Drug Administration (FDA) and European Medicines Agency (Hodi et al, 2010 ). Yet, the drawback of releasing the immune brake is induction of toxicity in healthy tissues. Currently, two CTLA-4 blocking antibodies are available: (Table I ). Up to 60% of the patients treated with aCTLA-4 develops immune-related adverse events (irAE), including rash, uveitis, colitis, and hepatitis. In a phase III trial with ipilimumab, 25% of the irAE were grade 3-4 toxicities and 10-15% were severe or life-threatening (Laurent et al, 2007) . Interestingly, these irAE appear to be associated with positive outcomes including tumour regression and prolonged time to relapse (Cousin et al, 2017) .
Studies have also demonstrated a role for CTLA-4 in hampering T cell immunity against haematological malignancies. AML blasts were shown to express CD86 and, to a lesser extent, CD80, the ligands for CTLA-4 (Norde et al, 2011) . The expression of CD86 by AML correlated with poorer outcome. The role of CTLA-4 in modulating immune responses in AML was further confirmed with the CTLA4 CT60 A/A genotype, i.e. a variant with stronger inhibitory function, which was associated with an increased incidence of AML relapse and reduced survival after allo-SCT (Perez-Garcia et al, 2009). Interestingly, CTLA-4 triggering by recombinant CD80 and CD86 could mediate AML apoptosis. Notably, in vitro blockade of CTLA-4 resulted in significantly enhanced T cell reactivity against autologous AML cells (Zhong et al, 2006) . In addition, combined CTLA-4 and PD-L1 (CD274, PDCD1LG1) blockade resulted in enhanced AML lysis in a mouse model of minimal residual disease (Saudemont & Quesnel, 2004) . In the setting of allo-SCT, the timing of CTLA-4 interference is of high importance, as demonstrated in mouse models. Treatment with anti-CTLA-4 shortly after allo-SCT increased the incidence and severity of graft-versus-host-disease (GVHD) in a CD28-dependent manner (Blazar et al, 1999) . In contrast, delayed administration augmented GVL immunity without substantially increasing GVHD-related side effects (Fevery et al, 2007) . Phase I trials exploring ipilimumab treatment after allo-SCT are summarized in Table II . Bashey et al (2009) demonstrated that a single infusion of ipilimumab, at a median of 1 year (range 0Á3-6Á5 years) after allo-SCT or donor lymphocyte infusion, in patients with recurrent or progressive haematological malignancies (including 2 AML patients) resulted in an objective clinical response in 3 out of 29 patients. Importantly, neither induction nor exacerbation of GHVD was reported, although 14% of the patients showed organ-specific adverse events. Analysis of the T cells before and after singledose ipilimumab administration revealed that CTLA-4 blockade was associated with increased conventional CD4 + T cell activation and intracellular CTLA-4 expression without affecting T regs numbers (Zhou et al, 2011a) . Another clinical trial enrolled 28 patients (12 with AML) with relapsed disease after allo-SCT at a median time of 675 days (range 198-1830 days) (Davids et al, 2016) . Here, 6 patients (21%) showed immune-related adverse events, of whom one patient died, and GVHD was observed in 4 patients (14%). Among 22 patients who received a dose of 10 mg/kg ipilimumab, 5 (23%) had a complete response, 2 (9%) had a partial response and 6 (27%) showed reduced tumour burden. Importantly, 4 of these patients had a durable response for more than 1 year. Responsiveness was associated with in situ infiltration of cytotoxic CD8 + T cells, decreased activation of T regs , and expansion of effector T cells in the blood. Currently, ipilimumab and tremelimumab are being evaluated in patients with AML or myelodysplastic syndrome (MDS) as a bridge-to-transplant, as well as in combination with allo-SCT and/or HMAs to improve anti-leukaemia immunity.
PD-1
Programmed death-1 (PD-1; PDCD1; CD279) is another key inhibitory player of the B7/CD28 family. It is expressed by activated CD4 + and CD8 + T cells, B cells, monocytes, dendritic cells (DC) and NK cells (Okazaki & Honjo, 2006) . PD-1 binds to PD-L1 (CD274; B7-H1; PDCD1LG1) and PD-L2 ( CD273; B7-DC; PDCD1LG2), with the highest affinity for PD-L2. PD-L1 can be widely expressed by haematopoietic and non-haematopoietic cells, although its expression is generally low on normal tissues (Dong et al, 2002) . In contrast, PD-L2 expression is restricted to APC, including DC and macrophages. Notably, PD-L1 expression was shown to be up-regulated by various tumour types upon exposure to inflammatory conditions (c-interferon; IFNc) or following activation of key oncogenic pathways involving phosphoinositide 3-kinase (PI3K) or mitogen-activated protein kinase (MAPK) . Similarly, PD-L2 was found to be expressed by certain solid tumours, including ovarian carcinoma and small cell lung cancer. Importantly, increased PD-L1/L2 expression by tumours was associated with poor prognosis (Hino et al, 2010) . Upon interaction with its ligands, the cytoplasmic signalling motifs of PD-1 become phosphorylated. This leads to recruitment of protein phosphatases, like SHP1 (PTPN6) and SHP2 (PTPN11), that mediate dephosphorylation of proximal TCR signalling molecules (Sheppard et al, 2004) . Consequently, CD28/TCRmediated activation of PI3K and Akt signalling is inhibited, resulting in suppression of T cell activation. Pre-clinical and clinical studies demonstrated an evident role for PD-1/PD-L1/L2 signalling in hampering immune responses in chronic viral infections and cancer. In 2014, the FDA approved the use of pembrolizumab and nivolumab, two PD-1 antagonists, for treatment of patients with metastatic melanoma (Robert et al, 2014) . Currently, antibodies blocking PD-1 (pembrolizumab, nivolumab), PD-L1 (BMS936,559 (MDX-1105), MPDL3280A (atezolizumab), MEDI4736 (durvalumab) and MSB0010718C (avelumab)) and PD-L2 (AMP-224) are under clinical investigation in melanoma and numerous other solid and haematological cancers. Importantly, nivolumab treatment resulted in objective and durable responses in 28% of patients with melanoma, 18% of patients with non-small cell lung cancer, and 27% of patients with renal cell carcinoma . Tumour cell PD-L1 expression seemed to correlate with response. Notably, the occurrence and severity of irAE upon PD-1 blockade appeared to be less than for aCTLA-4 treatment. Interestingly, in haematological malignancies, nivolumab and pembrolizumab showed objective responses in 87% and 65% of patients with relapsed/refractory Hodgkin lymphoma, respectively (Ansell et al, 2015; Armand et al, 2016) . The clinical efficacy can be attributed to high 9p24.1/ CD274/PDCD1LG2 gene amplification, causing strong PD-L1 expression levels by the Reed-Sternberg cells, and high T cell infiltration in the tumour microenvironment. PD-1/PD-L signalling was also shown to play a role in dampening anti-leukaemic immunity in AML. Multiple studies reported expression of PD-L1 and PD-L2 on human AML cells at diagnosis and relapse (Chen et al, 2008; Berthon et al, 2010) . Notably, ex vivo exposure to IFNc or chemotherapy resulted in up-regulation of PD-L1 expression on leukaemic blasts (Kronig et al, 2014) . Similarly, treatment with hypomethylating agents (decitabine/azacitidine) could also up-regulate PDCD1, CD274 and PDCD1LG2 expression in peripheral blood mononuclear cells of patients with myeloid malignancies (MDS and AML) . In a mouse minimal residual disease leukaemia model, PD-L1 checkpoint blockade resulted in improved survival (Saudemont & Quesnel, 2004) . Furthermore, enhanced tumourreactive T cell immunity and improved survival was demonstrated in AML-bearing PD-1 knockout mice and in wild type mice treated with antagonistic PD-L1 antibodies (Zhang et al, 2009) . Blocking the PD-1/PD-L signalling pathway in AML patients is currently under investigation (Table I ). In the allo-SCT setting, high PD-1 expression on donor-derived T cells was found to be associated with suboptimal GVL reactivity in mouse transplant models. Correspondingly, we and others found high PD-1 expression on allo-reactive MiHA-specific CD8 + T cells after allo-SCT (Norde et al, 2011; Hobo et al, 2012) . Subsequent ex vivo treatment with PD-1/PD-L1 blocking antibodies resulted in improved MiHA-specific CD8 + T cell reactivity, with most pronounced efficacy in relapsed patients (Norde et al, 2011) . In addition, MiHA-specific CD8 + T cell functionality could also be restored ex vivo and in mouse models by treatment with PD-L1/L2 silenced DC vaccines (Hobo et al, 2010; van der Waart et al, 2015) . Few clinical reports on PD-1 blockade in patients after allo-SCT have been published so far (Albring et al, 2017; McDuffee et al, 2017; Onizuka et al, 2017) . Haverkos et al (2017) treated 31 classical Hodgkin lymphoma patients with PD-1 blocking antibodies because of relapse post allo-SCT. Out of 30 evaluable patients, 15 had a complete response and 8 a partial response (77% overall response rate). Seventeen patients (55%) developed treatment-emergent GVHD following anti-PD-1 therapy, of whom 9 patients suffered from grade III-IV acute or severe chronic GVHD. Only 2 of these 17 patients showed a complete response to GVHD treatment, and 8 patients (26%) died because of GVHD. Interestingly, no GVHD was observed in the patients treated with a haploidentical HLAmismatched transplant and post-transplant cyclophosphamide and calcineurin inhibitor as GVHD prevention. It might be possible that the incidence of GVHD after checkpoint inhibitor administration varies depending on the type of GVHD prophylaxis used. These data emphasize the care that should be taken with checkpoint interference post allo-SCT. Although superior anti-tumour immunity can be achieved, the rapid onset of severe (treatment-refractory) GVHD is detrimental. Further investigation into the window of opportunity for PD-1 blockade post allo-SCT is warranted (Table II) . Currently, several trials are recruiting patients to investigate PD-1 blockade as monotherapy or in combination with aCTLA-4, KIR blocking antibodies or anti-tumour vaccines in AML patients as well as patients post allo-SCT (Table I) . Notably, care should be taken when combining checkpoint blockade with immunomodulatory agents. Recently, the FDA ordered a hold on all clinical trials exploring anti-PD-1 and immunomodulatory agents in multiple myeloma patients due to the death of myeloma patients treated with pembrolizumab combinations (Kegel, 2017) .
Novel checkpoint inhibitors
Numerous new receptor/ligand signalling pathways involved in dampening anti-tumour immunity have been identified as interesting targets for cancer immunotherapy. These include TIGIT (T cell immunoglobulin and ITIM domain), TIM-3 (T cell immunoglobulin and mucin domain-containing protein 3), LAG-3 (lymphocyte activation gene 3), BTLA (B-and T-lymphocyte attenuator) and CD200 receptor (CD200R).
TIGIT TIGIT (T cell immunoglobulin and ITIM domain) is a member of the immunoglobulin (Ig) superfamily that was discovered in 2009 (Stanietsky et al, 2009) . It is part of an intricate receptor network and competes with the CD96 and DNAM-1 (CD226) for binding to the poliovirus receptor (CD155) and nectin-2 (CD112). These ligands are expressed by (activated) DC, T cells and various non-haematopoietic cell types, including tumour cells (Gao et al, 2017) . CD112 and CD155 were shown to be expressed by DC located in para-follicular T cell regions in the lymph nodes, suggesting the involvement of these ligands in regulating peripheral tolerance (Pende et al, 2006) . Importantly, TIGIT and CD96 deliver The expression of TIGIT is restricted to lymphocytes, including activated T cells as well as memory T cells, T regs , NKT cells and NK cells (Stanietsky et al, 2009) . The inhibitory function of TIGIT has been primarily studied in NK cells and multiple mechanisms of action were identified. First, it was shown that the inhibitory effect of TIGIT was attributed to phosphorylation of its ITIM motif (Y231) and/ or ITT-like motif (Y225), resulting in activation of SHP-1 and subsequent inhibition of the PI3K and MAPK pathways (Stanietsky et al, 2009 ). This triggering of TIGIT by CD155-expressing target cells reduced NK cell-mediated cytokine secretion, degranulation and cytotoxicity (Stanietsky et al, 2009 ). In addition, TIGIT was shown to inhibit T cell activation and effector functionality by down-regulation of the TCR a-chain and CD3ɛ, causing disruption of the TCR complex (Joller et al, 2011) . Second, TIGIT can outcompete DNAM-1, due to its higher binding affinity for CD155, and thereby interfere with co-stimulatory signalling (Chan et al, 2014) . Third, TIGIT can interfere with cis-homodimerization of DNAM-1, thereby disrupting DNAM-1 co-signalling (Johnston et al, 2014) .
TIGIT is highly expressed by CD8 + tumour-infiltrating lymphocytes (TILs) in mouse and human non-small cell lung cancer, colon cancer and melanoma (Johnston et al, 2014; Chauvin et al, 2015) . Notably, TIGIT, TIM-3 and PD-1 coexpression marks CD8 + TILs with impaired cytotoxic activity and low capacity to produce TNF-a and IL-2 (Kurtulus et al, 2015) . Similarly, TIGIT expression on CD8 + T cells of AML patients was associated with poorer clinical outcome (Kong et al, 2016) . These T cells showed functional defects, including a poor capacity to produce cytokines, which could be reversed by TIGIT silencing. Correspondingly, TIGIT blockade resulted in enhanced expansion and effector functionality of CD8 + TILs of melanoma patients (Chauvin et al, 2015) . Furthermore, combined anti-TIGIT and anti-PD-1 treatment resulted in significantly improved cytokine production by CD8 + TILs in a mouse colon cancer model. Further studies are required to evaluate the efficacy of TIGIT blockade to restore T cell function and anti-leukaemia immunity in mouse AML models and AML patients.
TIM-3
TIM-3 (T cell immunoglobulin and mucin domain-containing protein 3) is a type I trans-membrane protein with a cytoplasmic tail that is devoid of ITIMs and ITSMs, the classical inhibitory motifs found in other co-inhibitory receptors (Monney et al, 2002) . In contrast, TIM-3 possesses a conserved region of five tyrosine residues, which upon phosphorylation interfere with downstream TCR signalling (Rangachari et al, 2012) . TIM-3 expression was originally found to be associated with IFN-c production by CD4 + and CD8 + T cells (Monney et al, 2002) . Normally, activated T cells show only transient TIM-3 expression, though this can persist upon chronic stimulation . In addition, TIM-3 is expressed by T regs , NK cells, macrophages and DC. Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) has been reported to stabilize TIM-3 expression by formation of a heterodimer (Huang et al, 2015) . Notably, TIM-3 has multiple ligands, including galectin-9, high mobility group protein B1 (HMGB1), and phosphatidyl serine. These ligands are expressed in a variety of tissues, including tumour cells (Zhu et al, 2005) . TIM-3 expression on type 1 T helper (Th 1 ) cells was found to have an important role in regulating T cell tolerance . Furthermore, high TIM-3 expression was observed on dysfunctional T cells from patients with chronic human immunodeficiency virus infection (Jones et al, 2008) . Sakuishi et al (2010) reported similar observations on TILs in their murine tumour models. Although, TIM-3 is rarely found on T regs in the periphery, the vast majority of tumour-infiltrating T regs express TIM-3. These T regs preceded the infiltration of dysfunctional CD8 + TILs.
Interestingly, TIM-3 + T regs possessed the most potent regulatory functionality. TIM-3 and PD-1 are usually co-expressed on TILs. In patients with advanced melanoma or non-small cell lung cancer these PD-1 + TIM-3 + TILs showed impaired proliferative capacity and cytokine production (Fourcade et al, 2014) . Importantly, these dysfunctional CD8 + T cells were also found in mouse tumour models, and interference with TIM-3 signalling resulted in improved anti-tumour immunity (Sakuishi et al, 2010; Fourcade et al, 2014) . In mouse and human AML, TIM-3 and PD-1 co-expression on T cells was associated with AML progression (Zhou et al, 2011b) . Furthermore, T cells of newly diagnosed AML patients showed higher expression of TIM-3, as compared to healthy controls . In addition, high coexpression of PD-1 and TIM-3 was associated with AML relapse in patients after allo-SCT (Kong et al, 2015) . In a mouse AML model, combined blockade of the TIM-3 and PD-1 signalling pathways, using a TIM-3 fusion protein and anti-PD-L1, resulted in reduced tumour burden and improved survival. Either therapy alone was insufficient to rescue the mice from AML-related death (Zhou et al, 2011b) . Recent studies also reported aberrant expression of TIM-3 on AML (stem) cells (Gao et al, 2014) . Furthermore, it has been proposed that TIM-3 can promote AML progression through direct suppression of CD4 + T cells by activating the IL-6/STAT3 pathway, resulting in inhibition of Th 1 polarization, or through activation of mTOR in AML cells (Goncalves Silva et al, 2015) . So far, TIM-3 blockade has not been explored in cancer patients yet.
LAG-3
LAG-3 (lymphocyte activation gene 3) is another co-inhibitory player of the Ig superfamily. It is a transmembrane protein with high structural homology to CD4. Similar to CD4, LAG-3 binds HLA-II molecules, though with higher affinity. LAG-3 is expressed on activated T cells and T regs , as well as a subset of NK cells, B cells and plasmacytoid DC (Workman et al, 2009) . In resting T cells, LAG-3 is localized in endosomal compartments (Bae et al, 2014) . Following T cell activation, LAG-3 is rapidly translocated to the cell surface. Here its expression is further regulated by metalloproteases, which cleave LAG-3 from the membrane. Within a tolerised environment, LAG-3 expression is retained on the surface of the activated T cells (Grosso et al, 2009 ). LAG-3 has cell intrinsic and extrinsic mechanisms to impair T cell functionality. Similar to CTLA-4, LAG-3 negatively regulates TCR-mediated signalling in effector T cells (Workman & Vignali, 2003) . LAG-3 associates with the CD3-TCR complex on the surface of activated CD4 + and CD8 + T cells and can thereby negatively regulate T cell proliferation and function. By means of interacting with HLA-II molecules, LAG-3 interferes with antigen-dependent activation of CD4 + T cells (Gandhi et al, 2006) . Interestingly, LAG-3 deficiency does not cause autoimmune disease in non-autoimmune-prone mouse strains nor affect T cell development or function, although reduced NK cell cytotoxicity has been observed. This phenomenon probably underlies the reduced ability of LAG-3-deficient mice to control tumour growth (Woo et al, 2012) . However, both LAG-3 blockade and LAG-3 deficiency accelerated the onset of diabetes in predisposed non-obese diabetic (NOD) mice (Bettini et al, 2011) . In accordance, combined LAG-3 and PD-1 deficiency induced severe autoimmunity and early death in different genetic backgrounds (Okazaki et al, 2011; Woo et al, 2012) . These studies support a non-redundant role of LAG-3 regulating T cell responses. PD-1 and LAG-3 co-expression has been shown to correlate with T cell dysfunctionality in chronic viral infections. TILs and tumour- shown to highly co-express LAG-3 and PD-1 (Tian et al, 2015) . Data on LAG-3 is limited in haematological malignancies. T cells of CD30L -, but not CD30L + , AML patients were reported to express LAG-3. In Hodgkin lymphoma, the presence of LAG-3 + CD4 and T reg subsets in the tumour environment correlated with defective tumour-reactive T cell responses (Gandhi et al, 2006) . Subsequent deletion of the LAG3 + CD4 + T cells augmented IFNc production and proliferation of tumour-reactive CD8 + T cells in vitro. Monoclonal antibodies directed against LAG-3 (BMS-986016 and LAG525) are currently evaluated, particularly in combination with anti-PD-1, in early phase clinical trials in patients with lymphoma and multiple myeloma (NCT01968109 and NCT02061761). To date, no trials have been initiated to investigate the potential of LAG-3 interference in AML.
BTLA
BTLA (B-and T-lymphocyte attenuator; CD272) is another co-inhibitory molecule belonging to the Ig superfamily, with structural similarities to CTLA-4 and PD-1 (Han et al, 2004) . BTLA has two conserved ITIM motifs in its cytoplasmic tail, which upon phosphorylation, recruit SHP1 and SHP2. These subsequently interfere with TCR and B cell receptor signalling (Krieg et al, 2005) . In addition, BTLA has been described to relay its inhibitory signals via GRB2 (Gavrieli & Murphy, 2006) . The expression of BTLA is mainly limited to lymphoid tissues, including T cells and B cells, though expression is also seen on mature DC and macrophages (Han et al, 2004) . BTLA is expressed on na€ ıve T cells, transiently up-regulated upon TCR engagement and subsequently down-regulated on fully activated T cells. Though, similar to LAG-3, BTLA levels remain high on tolerogenic T cells in vivo (Hurchla et al, 2005) . BTLA is part of a complex receptor/ligand network. Its ligand, herpesvirus entry mediator (HVEM; TNFRSF14), member of the tumour necrosis factor receptor superfamily, is expressed on T cells, B cells, NK cells, DC and myeloid cells including AML blasts . Next to BTLA, HVEM also interacts with Herpes simplex virus (HSV) glycoprotein D, lymphotoxin-a, CD160 and LIGHT (TNFSF14). While CD160 also delivers inhibitory signals, LIGHT acts as a co-stimulatory molecule (Pasero et al, 2012) . BTLA-deficient mice gradually develop elevated levels of self-antibodies, increased numbers of activated CD4 + T cells in the periphery and inflammatory cell infiltrates in multiple organs. This can progress to hepatitis-like disease and reduced survival (Oya et al, 2008) . The negative activity of BTLA on regulating T cell proliferation and cytokine production was further confirmed in in vitro studies (Han et al, 2004) . The formation of heterodimeric HVEM/BTLA complexes on na€ ıve T cells renders HVEM inaccessible to external ligands, thereby preventing co-stimulation (Cheung et al, 2009) . High BTLA expression on T cells is associated with poorer survival in patients with gastric cancer and hepatocellular carcinoma. In melanoma patients, tumour cells were found to exhibit high HVEM expression. In addition, BTLA and PD-1 were co-expressed on the melanoma-reactive CD8 + T cells.
Importantly, anti-BTLA synergized with PD-1 and TIM-3 blockade and improved proliferation and cytokine production by tumour-specific T cells in vitro, indicating a non-redundant role for BTLA (Fourcade et al, 2014) . Similarly, BTLA blockade combined with active immunization enhanced antitumour immunity and regression of adenocarcinomas in mice (Lasaro et al, 2011) . Interestingly, BTLA also plays a key role in modulating alloreactive T cell responses post allo-SCT. Single administration of an agonistic BTLA antibody, directly after allo-SCT, completely prevented GVHD induction in mice, without affecting GVT immunity. However, established GVHD could not be reversed by this treatment (Albring et al, 2010) . BTLA is highly expressed by MiHA-specific CD8 + T cells after allo-SCT. Notably, blocking the BTLA and/or PD-1 pathway resulted in restored proliferation and functionality of these MiHA-specific CD8 + T cells . Interestingly, some patients responded better to BTLA blockade as compared to PD-1 blockade, indicating the differential dominance of co-inhibitory signalling pathways among cancer patients. So far, no clinical trials have been initiated to investigate the safety, toxicity and efficacy of BTLA blockade for cancer treatment.
CD200R
CD200R, also known as the OX-2 receptor or CD200R1, is an inhibitory receptor with two Ig superfamily domains. Although it lacks the classical ITIM motifs, it has three tyrosine residues that can be phosphorylated. The exact mechanism of subsequent intracellular signalling has not been elucidated so far (Wright et al, 2000) . CD200R was originally described as a myeloid receptor, being expressed on macrophages, granulocytes and DC. Later it was also found to be expressed by T cells, B cells and NK cells (Rijkers et al, 2008) . The only known ligand for CD200R is CD200, a type I membrane glycoprotein. CD200 is expressed on thymocytes, activated T cells, B cells and DC, as well as non-haematopoietic cells, including hair follicle cells and vascular endothelial cells (Rygiel & Meyaard, 2012) . The CD200R/CD200 axis was found to be essential in preventing inflammatory responses and immune pathology during early microbial infection by elevating the threshold for immune activation.
Various human cancers were shown to over-express CD200, including renal carcinoma, head and neck carcinoma, testicular cancer, colon carcinoma and haematological malignancies. Over-expression of CD200 in AML and MDS cells was associated with increased relapse risk . In mouse experiments, CD200 expressing AML cells exhibited enhanced tumour growth, which could be limited by CD200 Fc administration (Gorczynski et al, 2001 ). In addition, in AML patients, CD200/CD200R signalling facilitated tumour immune evasion by impairing the frequencies and functionality of activated NK cells and memory T cells, as well as promoting the expansion of FoxP3 + T regs (Coles et al, 2012) . Notably, blockade of CD200 resulted in enhanced cytotoxicity and IFN-c production by NK cells, and restored the proliferative capacity of T cells (Coles et al, 2011) . Nevertheless, it should be emphasized that CD200R signalling not only dampens tumour-reactive immune responses, it also limits pro-tumourigenic inflammation. Hence, blockade of the CD200/CD200R pathway may not only improve anti-tumour immunity but also favour tumour progression due to enhanced pro-tumourigenic inflammation (Rygiel & Meyaard, 2012) .
Other checkpoint molecules (Lines et al, 2014) . VISTA-deficient mice exhibited enhanced spontaneous T cell activation and responsiveness to neo-antigen immunization . Activation of this signalling pathway prevented acute GVHD in a mouse transplant model, though the mechanism of action has not been elucidated yet (Flies et al, 2011) . Another interesting player is B7-H3, which inhibited T cell functionality in mouse models, where T H1 responses were preferentially stalled (Suh et al, 2003) . Next to the classical checkpoint molecules, innate receptors, including the killer cell immunoglobulin-like receptor (KIR) family and NKG2A, are involved in regulating tumour-reactive immune responses. Although, these receptors have been mostly studied in the context of NK cell functionality, they are also expressed by T cells. The KIR blocking antibody lirilumab augmented NK cell-mediated lysis of autologous tumour cells expressing HLA-C, including AML blasts and multiple myeloma cells, in vitro (Romagne et al, 2009) . Furthermore, lirilumab, in combination with anti-CD20, augmented NK cell reactivity against CD20 + B cell lymphoma cells in in vitro and in vivo mouse models (Aranda et al, 2014; Kohrt et al, 2014) . In elderly AML patients, lirilumab was shown to be safe in a dose-escalation study, capable of blocking KIRs with minimal toxicity and favourable effects on overall and relapse-free survival (Vey et al, 2012) . Mild and transient treatment-related adverse effects were observed in 15/23 patients, and 1/23 patients had grade 3-4 treatment-related adverse effects. Interestingly, OS was significantly improved in all 6 patients treated with ≥1 mg/kg lirilumab as compared to patients treated with ≤0Á3 mg/kg lirilumab. A phase II study investigating lirilumab as maintenance therapy in elderly AML patients has recently been completed (NCT01687387). Two trials with lirilumab, in combination with azacitidine or nivolumab, are ongoing in MDS and relapsed/refractory AML (NCT02599649 and NCT02399917 respectively). An alternative strategy to improve anti-tumour effects, that could potentially synergize with blockade of the inhibitory checkpoint molecules, is the activation of co-stimulatory pathways. Interesting candidates in this regard are OX40 (TNFRSF4; CD134), 4-1BB (TNFRSR9; CD137), CD27 and ICOS. These molecules are expressed by activated T cells, B cells, macrophages and APCs, and play a key role in the functional maturation of T cells (Burlion et al, 2017) . Studies evaluating the checkpoint landscape have shown OX40 and ICOS to be over-expressed in bone marrow of AML patients, especially in relapsed AML (Daver et al, 2016) . Agonistic antibodies targeting these stimulatory checkpoint receptors are currently being explored in advanced solid malignancies and lymphoma.
Future directions
Harnessing the immune system to battle tumour cells has accomplished a breakthrough in cancer treatment. Patients with end-stage disease show impressive clinical responses and benefit from improved overall survival. In haematological malignancies, allo-SCT was the first immunotherapy to demonstrate clinical efficacy with curative potential. Subsequent to CAR T cell therapy, the new kids on the block are the checkpoint inhibitors, which interfere with co-inhibitory signalling pathways involved in tumour immune escape. In this regard, CTLA-4 and PD-1/PD-L1 blockers successfully boosted anti-tumour immunity, resulting in tumour shrinkage and improved survival in solid and haematological malignancies, including melanoma, non-small cell lung cancer and lymphoma (Hodi et al, 2010; Postow et al, 2015b) . These impressive observations paved the way for further exploration of these checkpoint inhibitors as monotherapy or in combination with other therapies for cancer treatment. Furthermore, it initiated the identification of novel checkpoint players as targets for cancer immunotherapy.
Immunologically responsive tumours are considered to benefit most from checkpoint inhibitors. However, in daily practice, blockade of one checkpoint, such as PD-1, is not effective in all patients with immunologically responsive tumours. Furthermore, other patients only show delayed or mixed tumour regression . These observations may reflect differential dominance of immune editing mechanisms utilized by the tumour. For instance, lack or aberrant expression of LAA and MiHA, loss of HLA molecules or low expression of co-stimulatory molecules limits tumour recognition and subsequent activation of the T cells (Ahci et al, 2017) . Although AML holds strong immunogenic potential in the context of allo-SCT, in the autologous setting, combination therapy with chemotherapy, radiotherapy and/or immunomodulatory agents might be required to enhance expression and release of LAA, thereby allowing effective T cell priming and activation. The concept of combining idarubicin/cytarabine induction therapy with nivolumab treatment is currently studied in a phase II trial in patients aged <60 years with newly diagnosed AML (NCT02464657). Furthermore, a phase II study combines fludarabine/melphalan and auto-SCT with anti-PD-1 therapy in poor-risk AML patients in remission (NCT02771197). The combination of high-dose cytarabine with pembrolizumab is investigated in relapse/refractory AML (NCT02768792). Besides reduced tumour recognition, recruitment of immune suppressive cells, including T regs and myeloid-derived suppressor cells, may severely hamper productive anti-tumour immunity. Biomarkers to predict whether a patient will respond to and benefit from checkpoint interference are warranted. An interesting approach in this regard is PD-1/PD-L1 imaging (Heskamp et al, 2015) . Notably, as described above, (severe) irAEs are frequently observed, with profiles varying per type of inhibitor and underlying malignancy. Early detection of irAEs, followed by dose modification and/or immunosuppressive treatment depending on the type and severity of the irAE, according to published guidelines, is critical to master the double-edged sword of checkpoint inhibition, as reviewed by Davies and Duffield (2017) .
Combined targeting of checkpoint molecules
The key to success may lie in combination treatment with multiple antibodies targeting different checkpoint pathways. Recently, a double-blind, phase III randomized study investigated the combination of nivolumab and ipilimumab against the single treatment arms in 945 patients with treatmentna€ ıve advanced melanoma (Larkin et al, 2015) . Remarkably, the overall response rate for the combination therapy was 57Á6%, compared to 43Á7% in the nivolumab monotherapy and 19% in the ipilimumab monotherapy arms. Furthermore, this combined checkpoint therapy also improved progression-free survival. These data support the strength and potential synergy of interfering with multiple immunosuppressive mechanisms. Currently, anti-TIM-3/anti-PD-1 is being evaluated for clinical efficacy (Table I) . Similarly, combinations of co-inhibitory antagonists and/or agonists of costimulatory pathways are being explored. For instance, in a mouse ovarian cancer model, combined OX40 agonism and PD-1 blockade resulted in significant inhibition of tumour growth, while monotherapy was ineffective (Guo et al, 2014) .
Checkpoint interference and hypomethylating agents
Alternatively, it is highly interesting to combine checkpoint inhibition with HMA. In addition to direct anti-proliferative and pro-apoptotic effects on leukaemia cells, through reactivation of epigenetically silenced tumour suppressor genes, HMA possess immune promoting properties (Stahl et al, 2016) . Importantly, HMA have been shown to up-regulate expression levels of LAA and MiHA, including PRAME, MAGE-A, NY-ESO-1 (CTAG1B) and HA-1 (ARHGAP45). Thereby, they can improve AML recognition and promote priming of tumour-reactive T cells (Cruijsen et al, 2016; Srivastava et al, 2016) . Recently, we also observed that HMA, specifically decitabine, potentiate AML-reactive NK cell responses (Cany et al, 2017) . HMA may further modulate tumour immunogenicity by up-regulation of immune stimulatory molecules, including CD80, CD86, ULBP and MIC-A (Zimmer et al, 2008; Yang et al, 2014) . However, azacitidine was also reported to up-regulate PD-1, PD-L1 and PD-L2 gene expression in >50% of 61 evaluable patients with MDS/ AML during their first course of therapy . As the sum of stimulatory and inhibitory signals eventually determines the magnitude and functionality of tumour-reactive T and NK cell responses, it is highly attractive to favourably modulate this balance by combining HMA and checkpoint interference. The interest in this combination therapy is reflected by the numerous trials in AML and MDS that are currently ongoing, as summarized in Table I . These studies mainly focus on elderly patients and patients with higher-risk or relapse/refractory disease. Recently, the interim results of a phase II trial investigating azacitidine and nivolumab in relapsed/refractory AML patients were presented (NCT02397720). These first results showed comparable toxicity with other trials investigating checkpoint blockade, and improved outcome with a median survival of 9Á3 months for poor-risk patients (Daver et al, 2016 (Daver et al, , 2017 . Results of all ongoing trials are awaited with great interest to allow establishment of guidelines for treatment of AML patients with the combination of HMA and checkpoint interference.
Post-transplant checkpoint blockade
Despite the curative potential of allo-SCT, relapse rates are substantial. We and others have demonstrated the role of coinhibitory signalling pathways in hampering GVL immunity, providing rationale for checkpoint interference. Recently, the first studies on ipilimumab or nivolumab treatment in patients with relapsed AML and Hodgkin lymphoma post allo-SCT showed clinical benefit (Davids et al, 2016) . Nevertheless, these beneficial graft-versus-tumour responses were accompanied by severe treatment-refractory GVHD, especially for nivolumab. This might be related to the intensive prior treatments of these patients. Notably, no induction or exacerbation of GVHD was observed in the ipilimumab trial where patients were treated at late time-points after allo-SCT (Bashey et al, 2009) . These findings emphasize the importance of defining the optimal treatment window and best candidate antibodies for checkpoint inhibition post allo-SCT.
Conclusion
Co-inhibitory signalling pathways have been demonstrated to play a pivotal role in hampering immune responses in cancer patients, enabling tumour escape. Importantly, impressive clinical efficacy, with durable and highly potent tumour-reactive immune responses, have been obtained with checkpoint inhibitors in various solid and haematological malignancies.
Although highly promising, in AML, combinations with other treatment modalities are probably needed to improve the tumour immunogenicity, especially in the autologous setting. Further studies are warranted to identify the optimal combination treatment schedules for checkpoint inhibitors to boost anti-leukaemia immunity, without causing severe systemic toxicity. Mastering the double-edged sword of checkpoint inhibition, particularly in combination with HMA, might turn out to be a potent immunotherapeutic strategy to combat AML.
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